Cargando…

A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier

PURPOSE: Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominope...

Descripción completa

Detalles Bibliográficos
Autores principales: Trew, Geoffrey H., Pistofidis, George A., Brucker, Sara Y., Krämer, Bernhard, Ziegler, Nicole M., Korell, Matthias, Ritter, Henning, McConnachie, Alex, Ford, Ian, Crowe, Alison M., Estridge, Trudy D., Diamond, Michael P., De Wilde, Rudy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281664/
https://www.ncbi.nlm.nih.gov/pubmed/27844212
http://dx.doi.org/10.1007/s00404-016-4211-x
_version_ 1782503181052280832
author Trew, Geoffrey H.
Pistofidis, George A.
Brucker, Sara Y.
Krämer, Bernhard
Ziegler, Nicole M.
Korell, Matthias
Ritter, Henning
McConnachie, Alex
Ford, Ian
Crowe, Alison M.
Estridge, Trudy D.
Diamond, Michael P.
De Wilde, Rudy L.
author_facet Trew, Geoffrey H.
Pistofidis, George A.
Brucker, Sara Y.
Krämer, Bernhard
Ziegler, Nicole M.
Korell, Matthias
Ritter, Henning
McConnachie, Alex
Ford, Ian
Crowe, Alison M.
Estridge, Trudy D.
Diamond, Michael P.
De Wilde, Rudy L.
author_sort Trew, Geoffrey H.
collection PubMed
description PURPOSE: Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominopelvic surgery. METHODS: This first-in-human, prospective, randomized, multicenter, subject- and reviewer-blinded clinical study was conducted in 78 premenopausal women (18–46 years) wishing to maintain fertility and undergoing gynecologic laparoscopic abdominopelvic surgery with planned clinically indicated second-look laparoscopy (SLL) at 4–12 weeks. The first two patients of each surgeon received hydrogel, up to 30 mL sprayed over all sites of surgical trauma, and were assessed for safety and application only (n = 12). Subsequent subjects (n = 66) were randomized 1:1 to receive either hydrogel (Treatment, n = 35) or not (Control, n = 31); 63 completed the SLL. RESULTS: No adverse event was assessed as serious, or possibly device related. None was severe or fatal. Adverse events were reported for 17 treated subjects (17/47, 36.2%) and 13 Controls (13/31, 41.9%). For 95.7% of treated subjects, surgeons found the device “easy” or “very easy” to use; in 54.5%, some residual material was evident at SLL. For 63 randomized subjects who completed the SLL, adjusted between-group difference in the change from baseline adhesion score demonstrated a 41.4% reduction for Treatment compared with Controls (p = 0.017), with a 49.5% reduction (p = 0.008) among myomectomy subjects (n = 34). CONCLUSION: Spray application of a degradable hydrogel adhesion barrier during gynecologic laparoscopic abdominopelvic surgery was performed easily and safely, without evidence of clinically significant adverse outcomes. Data suggest the hydrogel was effective in reducing postoperative adhesion development, particularly following myomectomy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00404-016-4211-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5281664
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-52816642017-02-13 A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier Trew, Geoffrey H. Pistofidis, George A. Brucker, Sara Y. Krämer, Bernhard Ziegler, Nicole M. Korell, Matthias Ritter, Henning McConnachie, Alex Ford, Ian Crowe, Alison M. Estridge, Trudy D. Diamond, Michael P. De Wilde, Rudy L. Arch Gynecol Obstet General Gynecology PURPOSE: Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominopelvic surgery. METHODS: This first-in-human, prospective, randomized, multicenter, subject- and reviewer-blinded clinical study was conducted in 78 premenopausal women (18–46 years) wishing to maintain fertility and undergoing gynecologic laparoscopic abdominopelvic surgery with planned clinically indicated second-look laparoscopy (SLL) at 4–12 weeks. The first two patients of each surgeon received hydrogel, up to 30 mL sprayed over all sites of surgical trauma, and were assessed for safety and application only (n = 12). Subsequent subjects (n = 66) were randomized 1:1 to receive either hydrogel (Treatment, n = 35) or not (Control, n = 31); 63 completed the SLL. RESULTS: No adverse event was assessed as serious, or possibly device related. None was severe or fatal. Adverse events were reported for 17 treated subjects (17/47, 36.2%) and 13 Controls (13/31, 41.9%). For 95.7% of treated subjects, surgeons found the device “easy” or “very easy” to use; in 54.5%, some residual material was evident at SLL. For 63 randomized subjects who completed the SLL, adjusted between-group difference in the change from baseline adhesion score demonstrated a 41.4% reduction for Treatment compared with Controls (p = 0.017), with a 49.5% reduction (p = 0.008) among myomectomy subjects (n = 34). CONCLUSION: Spray application of a degradable hydrogel adhesion barrier during gynecologic laparoscopic abdominopelvic surgery was performed easily and safely, without evidence of clinically significant adverse outcomes. Data suggest the hydrogel was effective in reducing postoperative adhesion development, particularly following myomectomy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00404-016-4211-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-11-14 2017 /pmc/articles/PMC5281664/ /pubmed/27844212 http://dx.doi.org/10.1007/s00404-016-4211-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle General Gynecology
Trew, Geoffrey H.
Pistofidis, George A.
Brucker, Sara Y.
Krämer, Bernhard
Ziegler, Nicole M.
Korell, Matthias
Ritter, Henning
McConnachie, Alex
Ford, Ian
Crowe, Alison M.
Estridge, Trudy D.
Diamond, Michael P.
De Wilde, Rudy L.
A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
title A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
title_full A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
title_fullStr A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
title_full_unstemmed A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
title_short A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier
title_sort first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of actamax™ adhesion barrier
topic General Gynecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281664/
https://www.ncbi.nlm.nih.gov/pubmed/27844212
http://dx.doi.org/10.1007/s00404-016-4211-x
work_keys_str_mv AT trewgeoffreyh afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT pistofidisgeorgea afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT bruckersaray afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT kramerbernhard afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT zieglernicolem afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT korellmatthias afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT ritterhenning afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT mcconnachiealex afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT fordian afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT crowealisonm afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT estridgetrudyd afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT diamondmichaelp afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT dewilderudyl afirstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT trewgeoffreyh firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT pistofidisgeorgea firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT bruckersaray firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT kramerbernhard firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT zieglernicolem firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT korellmatthias firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT ritterhenning firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT mcconnachiealex firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT fordian firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT crowealisonm firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT estridgetrudyd firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT diamondmichaelp firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier
AT dewilderudyl firstinhumanrandomizedcontrolledsubjectandreviewerblindedmulticenterstudyofactamaxadhesionbarrier